PANDOLFO, Gianluca
 Distribuzione geografica
Continente #
EU - Europa 11.373
NA - Nord America 7.381
AS - Asia 4.313
SA - Sud America 1.253
AF - Africa 161
OC - Oceania 25
Continente sconosciuto - Info sul continente non disponibili 5
Totale 24.511
Nazione #
US - Stati Uniti d'America 7.226
RU - Federazione Russa 4.747
IT - Italia 2.064
SG - Singapore 1.751
CN - Cina 1.286
IE - Irlanda 1.212
SE - Svezia 1.097
BR - Brasile 1.067
DE - Germania 511
HK - Hong Kong 460
FR - Francia 417
PL - Polonia 296
UA - Ucraina 250
FI - Finlandia 241
VN - Vietnam 237
GB - Regno Unito 225
IN - India 142
NL - Olanda 78
CA - Canada 67
AR - Argentina 63
TR - Turchia 60
BD - Bangladesh 54
MX - Messico 52
ES - Italia 44
IQ - Iraq 43
ZA - Sudafrica 42
BE - Belgio 39
UZ - Uzbekistan 34
EG - Egitto 32
PK - Pakistan 32
JP - Giappone 31
MA - Marocco 29
ID - Indonesia 27
CO - Colombia 26
AT - Austria 25
EC - Ecuador 23
PH - Filippine 23
VE - Venezuela 22
AU - Australia 21
CH - Svizzera 20
CZ - Repubblica Ceca 20
AE - Emirati Arabi Uniti 15
PE - Perù 13
AZ - Azerbaigian 12
CL - Cile 12
LT - Lituania 12
PY - Paraguay 12
RO - Romania 12
BY - Bielorussia 11
DZ - Algeria 11
MY - Malesia 11
IL - Israele 10
SA - Arabia Saudita 10
GR - Grecia 9
LV - Lettonia 9
NP - Nepal 9
BO - Bolivia 8
KE - Kenya 8
DO - Repubblica Dominicana 7
JO - Giordania 7
TN - Tunisia 7
BG - Bulgaria 6
CI - Costa d'Avorio 6
ET - Etiopia 6
GE - Georgia 6
IR - Iran 6
KG - Kirghizistan 6
PA - Panama 6
SN - Senegal 6
LB - Libano 5
PS - Palestinian Territory 5
AL - Albania 4
AO - Angola 4
HN - Honduras 4
JM - Giamaica 4
KZ - Kazakistan 4
NG - Nigeria 4
NZ - Nuova Zelanda 4
OM - Oman 4
PT - Portogallo 4
SI - Slovenia 4
UY - Uruguay 4
AM - Armenia 3
BH - Bahrain 3
NO - Norvegia 3
RS - Serbia 3
SV - El Salvador 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BB - Barbados 2
BN - Brunei Darussalam 2
CG - Congo 2
CR - Costa Rica 2
GY - Guiana 2
KH - Cambogia 2
LK - Sri Lanka 2
ME - Montenegro 2
MK - Macedonia 2
NI - Nicaragua 2
PR - Porto Rico 2
TH - Thailandia 2
Totale 24.484
Città #
Moscow 1.310
Dublin 1.211
Ashburn 1.084
Singapore 1.009
Chandler 843
Dallas 760
Nyköping 570
Jacksonville 514
Beijing 494
Hong Kong 456
San Jose 380
Warsaw 278
Los Angeles 189
The Dalles 170
Dearborn 169
Rome 167
Princeton 164
Medford 160
New York 143
Cambridge 142
Lauterbourg 137
Messina 135
Munich 131
Milan 128
Bremen 126
Ann Arbor 124
Des Moines 119
Boardman 107
São Paulo 83
Buffalo 72
Houston 69
Ho Chi Minh City 68
Turku 64
Catania 62
Redondo Beach 57
Orem 53
Lancaster 49
Frankfurt am Main 47
Tianjin 47
Jinan 44
Hanoi 43
Rio de Janeiro 42
Shenyang 40
Wilmington 38
Guangzhou 37
Brussels 36
Palermo 34
Naples 33
Helsinki 32
Padova 32
Turin 32
Amsterdam 31
Santa Clara 31
Belo Horizonte 30
Tashkent 30
Udine 30
Woodbridge 30
Hyderabad 29
Cairo 28
San Mateo 28
Brasília 27
Chennai 27
Strasbourg 27
Brooklyn 26
Hebei 26
Tokyo 25
Zhengzhou 25
Bari 24
Council Bluffs 24
Dong Ket 24
Johannesburg 24
Nanjing 24
Seattle 24
Manchester 23
Pune 23
Vienna 23
Istanbul 22
Genoa 21
Toronto 21
London 20
Shanghai 20
Stockholm 20
Ningbo 19
Porto Alegre 19
Chicago 18
Haikou 18
Hangzhou 18
Phoenix 18
Taizhou 18
Verona 18
Washington 18
Baghdad 17
Mexico City 17
Montreal 17
Poplar 17
San Francisco 17
Bologna 16
Curitiba 16
Taranto 16
Denver 15
Totale 13.433
Nome #
Alessitimia, emozioni negative e comportamento sessuale 460
State-Trait Anger Expression Inventory (STAXI) e Defense Mechanisms Inventory (DMI): i limiti di un questionario di autovalutazione 437
Efficacia di un trattamento aggiuntivo con olanzapina nel disturbo ossessivo-compulsivo resistente agli SSRI 431
JUVENILE CRIMINALITY AND EXECUTIVE COGNITIVE FUNCTIONING IN AN ITALIAN SAMPLE OF LATE-ONSET ADOLESCENT DELINQUENTS 237
Il Burnout e l'emozione rabbia. 233
Association of the COMT synonymous polymorphism Leu136Leu and missense variant Val158Met with mood disorders. 233
Depressione e disturbi endocrini 225
Alessitimia, internet addiction disorder e mobile addiction in un campione di adolescenti 224
Abnormal illness behavior and Internet addiction severity: The role of disease conviction, irritability, and alexithymia. 220
Trattamento con agomelatina in soggetti affetti da fibromialgia: effetti sulla fenomenica depressiva, ansiosa e algica 218
Carcinoma mammario e disturbo depressivo. 215
Depressione, ansia e rabbia in soggetti affetti da diabete mellito di tipo 1 [Depression, anxiety and anger in patients with type 1 diabetes mellitus] 214
Advanced glycation end-products and advanced oxidation protein products in schizophrenia 214
Indagine statistico-epidemiologica per l’analisi dei rischi dipsicopatologia in giovani affetti da diabete mellito di tipo 1 213
Personality, Alexithymia, and Anger in a sample of adults affected by Type 1 Juvenile-Onset Diabetes. 208
Extrasensory perception experiences and childhood trauma: A rorschach investigation 207
CORRELATION ANALYSIS BETWEEN PERSONALITY AND RESILIENCE IN NON CLINICAL SUBJECTS. 205
Frazione polifenolica del bergamotto per il trattamento della sindrome metabolica nella schizofrenia: uno studio pilota [Bergamot polyphenolic fraction for the treatment of metabolic syndrome in schizophrenia: A pilot study] 204
Anger, Smoking Behavior, and the Mediator Effects of Gender: An Investigation of Heavy and Moderate Smokers. 203
Valutazione dell’umore e della personalità in un campione di forti fumatori 202
Augmentation con Aripiprazolo vs. placebo nel disturbo ossessivo compulsivo con sintomatologia residua in trattamento stabilizzato con SSRI 197
Augmentation con Lamotrigina in pazienti con schizofrenia resistente in trattamento con Clozapina 196
Acetyl-L-Carnitine Augmentation of Clozapine in Partial-Responder Schizophrenia: A 12-Week, Open-Label Uncontrolled Preliminary Study 196
Alexithymia, Negative Emotions, and Sexual Behavior in Heterosexual University Students from Italy 193
Morphometrical and morphological analysis of lateral ventricles in schizophrenia patients versus healthy controls. 191
Comportamento sessuale ed immaginario erotico in donne tossicodipendenti. 190
Depression, anxiety and anger in subtypes of irritable bowel syndrome patients 190
Psychopharmacotherapy in pregnancy and breastfeeding 188
Low-dose of bergamot-derived polyphenolic fraction (BPF) did not improve metabolic parameters in second generation antipsychotics-treated patients: Results from a 60-days open-label study 185
Cannabis and Sexual Behavior 185
Duloxetine in Psychiatric Disorders: Expansions Beyond Major Depression and Generalized Anxiety Disorder 185
Anger and Adolescence: A Psychometric Investigation on a Sample of Italian High School Students 184
The wounds of childhood: Early trauma subtypes, salience and hyperarousal in a sample of adult psychiatric patients 184
Agomelatine in the treatment of fibromyalgia: a 12-week, open-label, uncontrolled preliminary study. 183
Anger in health, benign breast disease and breast cancer: a prospective case-control study. 182
Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. 179
Reboxetine add-on to clozapine in treatment of negative symptoms of schizophrenia: a preliminary open-label study 176
Grief and the new DSM-5 clinical category: A narrative review of the literature. 175
Temperamento e alessitimia in un campione di soggetti antisociali con condotte di abuso. 173
Metabolic outcomes of Red yeast rice administration in patients treated with second-generation antipsychotics 171
Augmentation of clozapine with agomelatine in partial-responder schizophrenia: A 16-week, open-label, uncontrolled pilot study 170
Complicated grief: A systematic review of the last 20 years 167
Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study 167
Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. 165
Lifetime Psychiatric Comorbidity and Diagnostic Trajectories in an Italian Psychiatric Sample 165
Donepezil adjunctive treatment to clozapine for cognitive impairment in schizophrenia 163
Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. XVII Congresso Nazionale della Società Italiana di Neuropsicofarmacologia, Cagliari 22-25 Settembre 2010, p. 47. 163
Executive functions and basic symptoms in adolescent antisocial behavior: A cross-sectional study on an Italian sample of late-onset offenders. 163
Does personality matter? Temperament and character dimensions in panic subtypes 163
Aripiprazole augmentation of serotinin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study 162
The RS685012 Polymorphism of ACCN2, the Human Ortholog of Murine Acid-Sensing Ion Channel (ASIC1) Gene, is Highly Represented in Patients with Panic Disorder. 162
EW0245 Cognitive outcomes of Bergamot Polyphenolic Fraction (BPF) supplementation in schizophrenia: Preliminary data 162
Effetto di un trattamento con agomelatina sulle funzioni cognitive/esecutive di un campione di soggetti affetti da fibromialgia 160
The relationship between sexual behavior and internet addiction severity in a sample of heterosexual university students from Italy. 160
Bergamot Polyphenolic Fraction Supplementation Improves Cognitive Functioning in Schizophrenia 159
The role of alexithymia factors in adults with autism spectrum disorder: An explorative study 159
Antisocial personality disorder and subthresold symptomatology 158
Aripiprazole Plus Topiramate in Opioid-dependent Patients with Schizoaffective Disorder: An 8-week, Open-label, Uncontrolled, Preliminary Study 158
Negative Emotions in End-Stage Renal Disease: Are Anxiety Symptoms Related to Levels of Circulating Catecholamines? 158
Association between cortisol levels and pain threshold in systemic sclerosis and major depression 158
Central serous chorioretinopathy and personality characteristics: A systematic review of scientific evidence over the last 10 years (2010 to 2020) 158
Effect of aripiprazole augmentation of clozapine in schizophrenia: A double-blind, placebo-controlled study. 157
IL-33 in Mental Disorders 157
Esplorazione neuropsicologica del lobo prefrontale nel disturbo schizofrenico 156
Attentional and mnestic resistance to interference and the positive, negative and disorganization dimensions of schizophrenia: a correlation study 156
Focus on Disruptive Mood Dysregulation Disorder: A review of the literature 156
Aspetti funzionali dei recettori D1 Mesocorticali 152
Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: a randomized, placebo-controlled trial. 151
P.6.d.006 Aripiprazole plus topiramate in opioiddependent patients with schizoaffective disorder: evidence from a pilot study 151
Negative emotions in irritable bowel syndrome: which differences among IBS subtypes? 151
Esplorazione neuropsicologica delle funzioni esecutive 150
The Relationship between Anger and Heterosexual Behavior. An Investigation in a Nonclinical Sample of Urban Italian Undergraduates. 149
Funzioni neuropsicologiche e dimensioni psicopatologiche (positiva, negativa e disorganizzata) della schizofrenia. 148
The Relationship Between Anger and Sexual Behavior: A Review of Theories and Research 147
Meccanismi di difesa (D.M.I.) e temperamento (T.C.I.): studio di correlazione. 146
“Augmentation con Duloxetina vs. placebo in un campione di schizofrenici partial responders in trattamento stabilizzato con antipsicotici atipici”. 146
Criminalità giovanile: correlati neuropsicologici e psicopatologici. 146
Indici psicodiagnostici dei disturbi dello spettro autistico in età adulta: risultati preliminari 146
Effect of Red Yeast Rice on Cognitive Functioning in Schizophrenia: Data from a Pilot Study 144
Cognitive and Mood Effect of Alpha-Lipoic Acid Supplementation in a Nonclinical Elder Sample: An Open-Label Pilot Study 142
The Role of Basic Symptoms and Aberrant Salience in Borderline Personality Disorder 141
Red Yeast Rice (RYR) supplementation in patients treated with second-generation antipsychotics. 140
Augmentation of Clozapine With Ziprasidone in Refractory Schizophrenia: A Double-Blind, Placebo-Controlled Study. 139
Personality traits and emotional patterns in irritable bowel Syndrome 139
Correlazione tra sintomi di base e dimensione psicotica nel disturbo schizofrenico 138
Effect of Ziprasidone Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: A 12-Week, Open-Label Uncontrolled Preliminary Study 136
Effect of valproate on plasma concentrations of olanzapine in patients with psychotic disorders , July, 2009, MP 110.. 135
P.4.d.002 Effect of ziprasidone augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive–compulsive disorder 135
Indagine statistico-epidemiologica per l’analisi dei rischi di psicopatologia in adolescenti affetti da diabete mellito di tipo1. 131
Sharing the same perspective. Mental disorders and central serous chorioretinopathy: A systematic review of evidence from 2010 to 2020 131
Reboxetine adjuvant therapy in patients with schizophrenia showing a suboptimal response to clozapine: a 12-week, open-label, pilot study. 129
Metabolic Outcomes of Bergamot Polyphenolic Fraction Administration in Patients Treated with Second-Generation Antipsychotics: a Pilot Study 129
Comportamento sessuale ed immaginario erotico ad un test proiettivo in un campione di donne messinesi. 128
Pharmacokinetic interaction between duloxetine and second-generation antipsychotics in patients with psychotic disorders 128
L'instabilità affettiva nel Disturbo Borderline di Personalità e nella Ciclotimia. 127
Temperamento, carattere e motivazione sessuale. 127
COVID-19 Vaccination and Mental Disorders, What Has Been Accomplished and Future Direction 126
Avoidant personality disorder and delusions 123
EFFECT OF ZIPRASIDONE AUGMENTATION OF SEROTONIN REUPTAKE INHIBITORS IN TREATMENT-RESISTANT OBSESSIVE-COMPULSIVE DISORDER 123
Prevalence of Internet Addiction in a Sample of Southern Italian High School Students 123
Totale 17.585
Categoria #
all - tutte 73.519
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 73.519


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021255 0 0 0 0 0 0 0 0 0 111 74 70
2021/20221.319 22 145 30 51 58 12 74 52 66 273 152 384
2022/20233.523 230 334 155 226 379 335 38 182 1.469 40 96 39
2023/20241.321 93 160 103 134 112 245 57 64 36 99 71 147
2024/20253.964 70 77 151 261 191 180 92 732 916 214 418 662
2025/202610.889 654 709 818 667 910 2.287 1.448 1.433 1.460 503 0 0
Totale 24.783